Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.
Menarini Group will market Glenmark Pharmaceuticals’ Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray in 33 countries across Europe after the two firms entered into an exclusive licensing agreement.
The deal – which covers major European markets including France, Italy and Spain as well as the Balkan region –...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
